Julia Varga

Julia Varga

Auto-generated profile, based on publicly available information

Julia Varga

Institute for Tumor Biology and Experimental Therapy, Georg-Speyer-Haus, Frankfurt/Main, Germany 1

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 August 2014 in Nature
Verified
Journal Article
Closed access
PDF file
MSManon D. Schulz
Manon D. Schulz
ÇAÇiğdem Atay
Çiğdem Atay
JHJessica Heringer
Jessica Heringer
FRFranziska K. Romrig
Franziska K. Romrig
SSSarah Schwitalla
Sarah Schwitalla
MAMelek C. Arkan
Melek C. Arkan

25 September 2017 in Nature Cell Biology
Verified
Journal Article
Closed access
JVJulia Varga
Julia Varga
FGFlorian Greten
Florian Greten

1 July 2013 in Gastroenterology
Verified
Journal Article
Open access
PDF file
MQMichael Quante
Michael Quante
JVJulia Varga
Julia Varga
TWTimothy Wang
Timothy Wang
FGFlorian Greten
Florian Greten
Over the past decade, the microenvironment of gastrointestinal tumors has gained increasing attention because it is required for tumor initiation, progression, and metastasis. The tumor microenvironment has many components and has been recognized as one of the major hallmarks of epithelial cancers. Although therapeutic strategies for gastrointestinal cancer have previously focused on the epithelial cell compartment, there is increasing interest in reagents that alter the microenvironment, based on reported interactions among gastrointestinal epithelial, stromal, and immune cells during gastrointestinal carcinogenesis. We review the different cellular components of the gastrointestinal tumor microenvironment and their functions in carcinogenesis and discuss how improving our understanding of the complex stromal network could lead to new therapeutic strategies.

4 August 2020 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
JVJulia Varga
Julia Varga
ANAdele Nicolas
Adele Nicolas
VPValentina Petrocelli
Valentina Petrocelli
MPMarina Pesic
Marina Pesic
AMAbdelrahman Mahmoud
Abdelrahman Mahmoud
FGFlorian Greten
Florian Greten
Recently, a transcriptome-based consensus molecular subtype (CMS) classification of colorectal cancer (CRC) has been established, which may ultimately help to individualize CRC therapy. However, the lack of animal models that faithfully recapitulate the different molecular subtypes impedes adequate preclinical testing of stratified therapeutic concepts. Here, we demonstrate that constitutive AKT activation in intestinal epithelial cells markedly enhances tumor invasion and metastasis in Trp53ΔIEC mice (Trp53ΔIECAktE17K) upon challenge with the carcinogen azoxymethane. Gene-expression profiling indicates that Trp53ΔIECAktE17K tumors resemble the human mesenchymal colorectal cancer subtype (CMS4), which is characterized by the poorest survival rate among the four CMSs. Trp53ΔIECAktE17K tumor cells are characterized by Notch3 up-regulation, and treatment of Trp53ΔIECAktE17K mice with a NOTCH3-inhibiting antibody reduces invasion and metastasis. In CRC patients, NOTCH3 expression correlates positively with tumor grading and the presence of lymph node as well as distant metastases and is specifically up-regulated in CMS4 tumors. Therefore, we suggest NOTCH3 as a putative target for advanced CMS4 CRC patients.

16 June 2017 in Cell Death & Differentiation
Verified
Journal Article
Open access
PDF file
PCPatrizia Cammareri
Patrizia Cammareri
DVDavid F Vincent
David F Vincent
MHMichael C Hodder
Michael C Hodder
RRRachel A Ridgway
Rachel A Ridgway
CMClaudio Murgia
Claudio Murgia
OSOwen Sansom
Owen Sansom
Recent studies have suggested increased plasticity of differentiated cells within the intestine to act both as intestinal stem cells (ISCs) and tumour-initiating cells. However, little is known of the processes that regulate this plasticity. Our previous work has shown that activating mutations of Kras or the NF-κB pathway can drive dedifferentiation of intestinal cells lacking Apc. To investigate this process further, we profiled both cells undergoing dedifferentiation in vitro and tumours generated from these cells in vivo by gene expression analysis. Remarkably, no clear differences were observed in the tumours; however, during dedifferentiation in vitro we found a marked upregulation of TGFβ signalling, a pathway commonly mutated in colorectal cancer (CRC). Genetic inactivation of TGFβ type 1 receptor (Tgfbr1/Alk5) enhanced the ability of KrasG12D/+ mutation to drive dedifferentiation and markedly accelerated tumourigenesis. Mechanistically this is associated with a marked activation of MAPK signalling. Tumourigenesis from differentiated compartments is potently inhibited by MEK inhibition. Taken together, we show that tumours arising in differentiated compartments will be exposed to different suppressive signals, for example, TGFβ and blockade of these makes tumourigenesis more efficient from this compartment.

12 June 2014 in FEBS Letters
Verified
Journal Article
Open access
JVJulia Varga
Julia Varga
TOTiago De Oliveira
Tiago De Oliveira
FGFlorian Greten
Florian Greten
Tumor cell plasticity is an event that has been observed in several malignancies. In fact, most of the solid tumors are characterized by cellular heterogeneity and undergo constant changes as the tumor develops. The increased plasticity displayed by these cells allows them to acquire additional properties, enabling epithelial‐mesenchymal transitions, dedifferentiation and the acquisition of stem cell‐like properties. Here we discuss the particular importance of an inflammatory microenvironment for the bidirectional control of cellular plasticity and the potential for therapeutic intervention.